Follow-Up To REDUCE Study Shows Low Rate Of Prostate Cancer Diagnosis
Analysis of 2 Years of Additional Data on Dutasteride Treatment Reported in The Journal of Urology® The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Follow-up to REDUCE study shows low rate of prostate cancer diagnosis
(Elsevier Health Sciences) The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness. Results from a follow-up study are now published in the Journal of Urology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2013 Category: Cancer & Oncology Source Type: news
New Lawsuit on Avodart Prostate Cancer: Now, AttorneyOne Can Provide...
According to court documents, on December 6th, 2012, a Texas resident and his wife filed a lawsuit in Pennsylvania Eastern District Court alleging he developed prostate cancer from his use of the drug...(PRWeb December 31, 2012)Read the full story at http://www.prweb.com/releases/2012/12/prweb10278666.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 1, 2013 Category: Pharmaceuticals Source Type: news
